ADVITOS GmbH

Key People

• Dr. Claus Jessen - Chief Executive Officer
• Frank Nthel - Chief Financial Officer
• Tobias Bingold - Chief Medical Officer
• Christoph Htege - Head of Research & Development
• Jakob Miedaner - Head of Supply Chain
• Annekatrin Richert - Medical Director

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in medical technology and business management.

Dr. Claus Jessen, the CEO, has a strong background in mechanical engineering and healthcare, having held significant positions at Fresenius Medical Care. The CFO, Frank Nthel, and other key members bring valuable expertise in their respective fields, contributing to a robust leadership team.

Clinical Need

Aspect: Very Strong
Summary: ADVITOS addresses a critical need in intensive care by providing multi-organ support for patients with multiple organ failure.

Multi-organ failure is a leading cause of death in intensive care units, with approximately 60% of ICU deaths attributed to it. ADVITOS's ADVOS therapy offers simultaneous support for the liver, lungs, and kidneys, addressing this urgent clinical need effectively.

Competition

Aspect: First mover
Summary: ADVITOS is pioneering in the field of integrated multi-organ support devices.

As the first to market with a device offering simultaneous support for multiple organs, ADVITOS has the advantage of setting industry standards. However, this position also requires significant efforts in market education and adoption.

Technical Challenge

Aspect: Very Complex
Summary: Developing and implementing a device that supports multiple organs simultaneously involves significant technical complexity.

The ADVOS device integrates support for the liver, lungs, and kidneys, requiring sophisticated engineering and medical expertise. Ensuring reliability and efficacy across diverse patient conditions adds to the technical challenges.

Patent

Aspect: Very Strong
Summary: ADVITOS holds a CE-marked and globally patented technology for multi-organ support.

The company's ADVOS technology is both CE-marked and globally patented, indicating robust intellectual property protection. This strengthens ADVITOS's position in the market and may deter potential competitors.

Financing

Aspect: Well-funded
Summary: ADVITOS has secured significant funding from reputable investors, supporting its growth and development plans.

The company completed a 20 million financing round led by Crdit Mutuel Equity and the European Innovation Council Fund. This funding is intended to accelerate growth and expand market reach.

Regulatory

Aspect: 510k/PMA + Reimbursement
Summary: ADVITOS's technology is CE-marked, indicating compliance with European regulatory standards.

The CE marking allows ADVITOS to market its device within the European Economic Area. However, entering markets like the United States will require navigating additional regulatory pathways, such as the FDA's 510(k) or PMA processes.

Opportunity Rollup

Odds of Success

3.15

Peak Market Share

3.95

Segment CAGR

5.8%

Market Segment

Therapeutic Devices

Market Sub Segment

Multi-Organ Support Devices

Key Takeaway

ADVITOS's innovative multi-organ support device addresses a critical need in intensive care, backed by strong leadership and patent protection. While facing technical and regulatory challenges, the company's solid funding and market potential position it well for future growth.